Oxford Textbook of Rheumatoid Arthritis

Erscheinungsjahr 2020
ISBN: 978-0-19-883143-3
Verlag: Oxford University Press

Buch, Englisch, 576 Seiten, Format (B × H): 228 mm x 284 mm, Gewicht: 1658 g

This brand new textbook of rheumatoid arthritis (RA) is an important addition to the Oxford Textbooks in Rheumatology series, and provides a comprehensive overview of both the scientific and clinical aspects of the disease. Divided into eight sections - from the history, diagnosis, and epidemiology of the disease, through the pathogenesis, clinical presentation, and assessment to treatments and management strategies, both drug- and non-drug based - each chapter is written by leading clinicians and scientists in the field to deliver a contemporary view of RA.

During the past two decades there have been revolutionary changes in the understanding and management of rheumatoid arthritis, in particular the development of biological treatments. This has had wide-ranging effects on almost all aspects of treatment, from effectiveness and intensity to the nature and the cost. Providing a comprehensive account of the modern ideas about the disease, the Oxford Textbook of Rheumatoid Arthritis is a key new addition to the literature, with each chapter providing a detailed background, key recent advances, and areas of doubt and future developments.

Featuring over 170 photographs, radiological images, and clinical charts to aid both diagnosis and illustrate the rationale behind key scientific studies, this new title will prove an indispensable resource for specialist rheumatologists, trainees in rheumatology, and other members of the multi-disciplinary team.

Autoren/Hrsg.

Scott, David L.

Galloway, James

Cope, Andrew

Pratt, Arthur

Strand, Vibeke

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Physiotherapie, Physikalische Therapie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Rheumatologie, Muskelerkrankungen

Inhaltsverzeichnis

- 1. History, diagnosis, and epidemiology

- 1: David L. Scott: The history of rheumatoid arthritis

- 2: Daniel Aletaha and Helga Radner: Diagnosis

- 3: James Gwinnutt and Deborah Symmons: The descriptive epidemiology of rheumatoid arthritis

- 4: Lars Klareskog and Lars Alfredsson: Modifiable and other risk factors for rheumatoid arthritis: a basis for prevention and better therapy

- 2. Pathogenesis

- 5: Anne Barton: Genetics and epigenetics of rheumatoid arthritis

- 6: Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris Buckley: Dysregulation of synovial fibroblasts in rheumatoid arthritis

- 7: Tom W. J. Huizinga: Autoantibodies in rheumatoid arthritis

- 8: Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas: Dendritic cells and T cells in rheumatoid arthritis

- 9: Ukrike Steffen and Georg Schett: Mechanisms of bone and cartilage destruction

- 10: Marina Frleta-Gilchrist and Iain B. McInnes: Cytokines and other mediators

- 3. Clinical presentation

- 11: Annette van der Helm-van Mil: Clinical features of rheumatoid arthritis

- 12: Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan van Schaardenburg: Pre-rheumatoid arthritis

- 13: Katherine MacDonald, Jennifer Hannah, and James Galloway: Non-articular manifestations of rheumatoid arthritis

- 14: Kimme Hyrich and Sarah Skeoch: Comorbidity in rheumatoid arthritis

- 4. Disease assessment

- 15: Josef Smolen: Disease activity assessment in rheumatoid arthritis

- 16: Douglas Veale and Ursula Fearon: Synovial biopsies

- 17: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: Radiography in rheumatoid arthritis

- 18: Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin: Ultrasound in rheumatoid arthritis

- 19: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: MRI in rheumatoid arthritis

- 5. Impact on life

- 20: Kathryn A. Gibson and Theodore Pincus: Patient physical function in rheumatoid arthritis

- 21: Emma Dures and Neil Basu: Fatigue

- 22: David L. Scott and Allan Wailoo: Health economics

- 23: Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James Galloway: Rheumatoid arthritis and work

- 6. Non-drug treatments

- 24: Lindsay Bearne and Christina Opava: Exercise

- 25: Heidi Siddle and Anthony Redmond: Foot health

- 26: Alison Hammond, Joanne Adams, and Yeliz Prior: Occupational therapy

- 27: Marieke M.J.H. Voshaar: Self-management: a patient's perspective

- 7. Drug treatments

- 28: Mark D Russell and Nidhi Sofat: Analgesics, Opioids, and NSAIDs

- 29: Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J. Bijlsma, and José A. P. da Silva: Glucocorticoids

- 30: David L. Scott: Conventional disease modifying drugs

- 31: Peter Taylor and Nehal Narayan: Tumour necrosis factor inhibitors

- 32: Neelam Hassan and Ernest Choy: Interleukin-6 inhibitors

- 33: Yuzaiful Yusof, Edward Vital, and Maya Buch: B-cell therapies

- 34: Vibeke Strand, Jeffrey Kaine, and John Isaacs: Biosimilars

- 35: Meghna Jani, John Isaacs, and Vibeke Strand: Immunogenicity in response to biologic agents

- 36: Katie Bechman, James Galloway, and Peter Taylor: The use of JAK inhibitors in the treatment of rheumatoid arthritis

- 37: Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler: Combination therapy in rheumatoid arthritis

- 38: Jeremy Sokolove: Translation of new therapies: from bench to bedside

- 39: James Galloway and Mark Yates: Adverse events in clinical studies in rheumatoid arthritis

- 8. Management and outcomes

- 40: Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew Cope: Prevention of rheumatoid arthritis

- 41: Kenneth F Baker and Arthur G Pratt: Treatment targets and remission

- 42: David L. Scott: Clinical outcomes

- 43: Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K. Kvien: Clinical guidelines

- 44: Angela Zink and Anja Strangfeld: European biologics registers

- 45: Jeff Greenberg and Sheetal Patel: Voluntary patient registries

Über Autor(innen)

David L. Scott is Professor of Clinical Rheumatology at King's College London. He trained in medicine and rheumatology in Leeds and Birmingham and subsequently held a fellowship at St Bartholomew's Hospital in London. His current academic focus spans the outcomes of rheumatoid arthritis and the impact of intensive treatment in improving outcomes in clinical trials.

James Galloway is Senior Lecturer in Rheumatology at King's College London and Honorary Consultant Rheumatologist at King's College Hospital. After training in medicine and rheumatology in Bristol and Manchester he held a fellowship at the Arthritis Research UK Epidemiology Unit in Manchester. His current academic focus is on large observational studies of arthritis and treatment risks including infections

Andrew Cope is Arthritis Research UK Professor of Rheumatology at King's College London and Honorary Consultant Rheumatologist at Guy's and St Thomas's Hospital. After training in medicine and rheumatology in London he held fellowships at the Kennedy Institute of Rheumatology and Stanford University. His current academic focus spans laboratory studies, clinical trials and observational studies with an emphasis on understanding the immunobiology of inflammatory arthritis.

Arthur Pratt is Clinical Fellow in the Institute of Cellular Medicine and Honorary Consultant Rheumatologist at the Freeman Hospital in Newcastle. He trained in medicine and rheumatology in Leeds and Newcastle. Subsequently he was a training fellow and National Institute for Health Clinical Lecturer at Newcastle University. His current academic focus is clinical and laboratory assessments and predictors in early inflammatory arthritis.

Vibeke Strand is Adjunct Clinical Professor, in the Division of Immunology and Rheumatology at Stanford University. She is a clinical rheumatologist and acts as a consultant in biopharmaceutics, clinical research, and regulatory affairs to many pharmaceutical and biotech companies. After graduating from Swarthmore College she trained in medicine and rheumatology at University of California San Francisco School of Medicine. Her current academic focus spans clinical trial design, development of outcome measures with an emphasis on patient reported outcomes and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases. She gives particular emphasis to translating basic research findings into rationally designed clinical trials, evaluating their results and helping patients access new treatments.